Breaking Down Aedifica SA Financial Health: Key Insights for Investors

Aedifica's mid‑2025 figures demand attention: first‑half rental income rose by 9% to €180.8 million with a 3.0% like‑for‑like rise, its portfolio was valued near €6.2 billion (613-615 healthcare properties across seven countries) and the weighted average unexpired lease term sits at a striking 18 years alongside a 100% occupancy rate - while EPRA Earnings reached €123.3 million (or €2.59 per share) for H1 2025, the company reports an average cost of debt of 2.2%, a debt‑to‑assets ratio around 41.2% with €614-€673 million of committed credit headroom, and active asset rotation with disposals totalling roughly €105-€125 million and planned investments of €160 million (with €71 million remaining), all signals that investors should scrutinize the detailed revenue trends, profitability metrics, leverage profile and valuation movements that follow.

Aedifica SA (AED.BR) - Revenue Analysis

• Rental income H1 2025: €180.8 million (+9.0% vs H1 2024)
• Like‑for‑like rental income growth H1 2025: +3.0%
• Q1 2025 rental income: €93.0 million (+13% vs Q1 2024)
• Portfolio value (30 Jun 2025): ~€6.2 billion
• Number of properties: 613 healthcare assets across 7 countries
• Weighted average unexpired lease term (WAULT): 18 years
• Occupancy rate: 100%
• Divestments (strategic rotation): 31 properties (incl. full Swedish portfolio) for ~€105 million

• Primary revenue drivers: long WAULT, full occupancy, indexation mechanisms and selective acquisitions/asset rotations.
• Near‑term volatility factors: portfolio rotation proceeds and timing, country mix moves from disposals, and macro rental indexation differentials across markets.
• Investor considerations: earnings quality supported by 100% occupancy and 18‑year WAULT; monitor impact of divestments (€105m) on recurring income versus redeployment returns.

Aedifica SA (AED.BR) - Profitability Metrics

Aedifica delivered continued profitability momentum through 2025, supported by steady rental growth, controlled financing costs and resilient EPRA earnings per share.

• EPRA Earnings H1 2025: €123.3 million (up 4% vs. 30 Jun 2024) - €2.59 per share.
• EPRA Earnings Q3 2025 (YTD through Sep 30): €185.8 million (up 4% vs. 30 Sep 2024) - €3.91 per share.
• Estimated EPRA Earnings FY 2025: €5.01 per share; proposed dividend €4.00 per share - payout ratio 80%.
• Like-for-like rental income increase (first 9 months 2025): +3.1%.
• Average cost of debt (incl. commitment fees) as of 30 Sep 2025: 2.2%.
• Interest coverage ratio: 3.5x.

Key investor takeaways are summarized below:

• Steady EPRA EPS growth (+4% YoY for both H1 and Q3 YTD comparisons) underpins distributable earnings capacity.
• The proposed €4.00 dividend at an 80% payout ratio signals a shareholder-focused cash distribution policy while retaining room for operational reinvestment.
• Like-for-like rental growth of 3.1% supports recurring income - a core driver of EPRA metrics.
• Low average cost of debt (2.2%) combined with a 3.5x interest coverage ratio reduces refinancing risk and preserves earnings stability.

For context on corporate purpose and longer-term strategy, see: Mission Statement, Vision, & Core Values (2026) of Aedifica SA.

Aedifica SA (AED.BR) - Debt vs. Equity Structure

• Debt-to-assets: 41.2% (as of September 30, 2025).
• Debt-to-assets: 39.9% (Q1 2025), decreasing to 39.5% after disposal proceeds were applied.
• Total shareholder equity: €3.6 billion.
• Total debt: €2.5 billion - implying a debt-to-equity ratio of 69.3%.
• Average cost of debt (including commitment fees): 2.2% (as of March 31, 2025).
• Credit rating: BBB (investment-grade) with a stable outlook from S&P.

• Liquidity and covenant buffers: substantial committed headroom (€614M / €673M disclosures) combined with disposal proceeds that lowered leverage in Q1 2025.
• Cost profile: low average cost of debt (2.2%) supports spread preservation and interest coverage relative to rental income streams.
• Capital mix implications: with €3.6B equity vs €2.5B debt, Aedifica's balance sheet shows room to raise additional debt without breaching typical REIT leverage norms, while keeping investment-grade rating considerations in mind.

Aedifica SA (AED.BR) - Liquidity and Solvency

Aedifica's liquidity and solvency profile reflects a balance between conservative leverage and available committed funding to support growth and working capital needs. Key metrics and recent movements are summarized below.

• Debt-to-assets ratio: 41.2% (as of 30 Sep 2025).
• Debt-to-assets trend in 2025 Q1: 39.9% (Q1 2025) decreasing to 39.5% after disposal proceeds.
• Total shareholder equity: €3.6 billion; Total debt: €2.5 billion; Debt-to-equity: 69.3%.
• Average cost of debt (including commitment fees): 2.2% (as of 31 Mar 2025).
• Credit rating: BBB (S&P), stable outlook.
• Committed credit line headroom cited: €614 million and alternative disclosure of €673 million available for capex and liquidity needs.

For broader investor context on ownership and strategic positioning, see: Exploring Aedifica SA Investor Profile: Who's Buying and Why?

Aedifica SA (AED.BR) - Valuation Analysis

• Total portfolio value: €6.2 billion across 615 healthcare properties in seven countries.
• Like-for-like valuation change: +0.4% in Q3 2025; +0.8% year-to-date.
• Occupancy rate: 100% - indicating full utilization of income-generating assets.
• Weighted average unexpired lease term (WALT): 18 years - long-dated cashflow visibility.
• Strategic rotation: 33 properties divested for €125 million during the period.
• Average cost of debt (including commitment fees): 2.2%.
• Interest coverage ratio: 3.5x - comfortable coverage of interest expenses.

Aedifica SA (AED.BR) - Risk Factors

• Leverage snapshot: debt-to-assets 41.2% (as of Sep 30, 2025), highlighting moderate balance-sheet gearing.
• Credit profile: BBB investment-grade rating with a stable outlook (S&P), supporting access to capital but vulnerable to deterioration in operating cash flow or asset valuations.
• Refinancing and liquidity: €673 million of headroom on committed credit lines to cover capex and short-term liquidity needs, reducing near-term refinancing pressure.
• Cost of debt: average all-in cost (including commitment fees) 2.2% as of Mar 31, 2025 - relatively low but sensitive to market rate increases and future repricing.

• Interest-rate risk - variable-rate exposure and upcoming refinancings could lift the group's effective interest burden above the 2.2% average if market rates rise materially.
• Refinancing risk - although headroom (€673m) cushions near-term needs, larger or earlier-than-expected maturities could require market access at less favorable terms.
• Asset-value and rental-market risk - declines in healthcare real-estate valuations or rental income (occupancy, tenant credit, public funding shifts) would compress equity and raise leverage ratios.
• Liquidity and covenant risk - changes in covenant metrics tied to net debt/EBITDA or loan-to-value could trigger restrictions or accelerated repayment if operating metrics weaken.
• Concentration risk - geographic or tenant concentration in specific healthcare subsegments could amplify localized shocks.
• Rating sensitivity - a downgrade from BBB would raise funding costs and reduce market access, increasing rollover and liquidity risk.

• Monitor upcoming debt maturities and the schedule of committed facilities to assess refinancing needs against the €673m headroom.
• Track macro interest-rate trends relative to the 2.2% average cost of debt and any shift in fixed vs. floating mix in the debt book.
• Watch operational metrics (occupancy, rent collection, tenant mix) that feed valuation and covenant tests affecting the BBB rating.

Aedifica SA (AED.BR) Growth Opportunities

• Investment program size: €160 million in pre-let development projects and acquisitions in progress, with €71 million remaining to be invested.
• H1 2025 additions: eight new projects totaling approximately €46 million added to the investment program.
• Recent acquisition: portfolio of six Finnish care properties acquired for €38 million.
• Asset rotation: 33 properties divested for €125 million to reallocate capital into higher-yielding or strategic assets.
• Portfolio scale: real estate portfolio valued at €6.2 billion as of 30 September 2025, comprising 615 healthcare properties across seven countries.
• Credit profile: BBB investment-grade rating with a stable outlook reaffirmed by S&P.

These elements support Aedifica's capacity to pursue accretive investments while maintaining balance sheet resilience. The mix of active development, selective acquisitions (including market entries such as the Finnish portfolio), and systematic disposals highlights a portfolio-shaping approach that targets long-term income growth and risk management.

Investors evaluating near-term growth potential should consider the remaining €71 million of committed program capacity, the ~€46 million pipeline inflow in H1 2025, and the strategic redeployment of proceeds from €125 million of disposals. For context on corporate purpose and long-term orientation, see Mission Statement, Vision, & Core Values (2026) of Aedifica SA.